An injectable medicine in the class of pharmaceuticals known as class II anabolic androgenic steroids is nandrolone decanoate, sometimes referred to as 19-nortestosterone (AAS). As synthetic derivatives of the naturally occurring male hormone testosterone, the medications that come under class II AAS are collectively referred to as 19-nortestosterone derivatives. AAS drugs like Nandrolone decanoate were created to have more anabolic and less androgenic properties because the primary functions of testosterone in the human male are to support the development of secondary sexual characteristics (androgenic effects) during puberty and the development as well as maintenance of muscle mass (anabolic effects). 1

Nandrolone, which was first created and reported by Birch in 1950, resembles testosterone chemically and structurally. The absence of a methyl group at carbon C-19 in nandrolone is the only chemical difference between it and testosterone. Because of its demethylation at C-19, nandrolone decanoate has substantially stronger anabolic effects than testosterone but only mild androgenic effects. 2

The management of refractory anemia that is unresponsive to other forms of therapy is one of the primary indications for the clinical use of injectable nandrolone decanoate; nandrolone stimulates the production of erythropoietin by the kidneys, which results in an increased mass and volume of red blood cells. Nandrolone may also encourage tissue growth and the eventual increase of muscle mass in patients with chronic wasting disorders like cancer. The medical treatment of osteoporotic postmenopausal women may potentially involve the use of nandrolone. 3 4

Testosterone Cypionate / Testosterone Enanthate
Testosterone was the first anabolic steroid ever produced, and testosterone cypionate is a long-ester, slow-acting injectable testosterone molecule that is frequently used to treat hypogonadism, or low testosterone levels, and numerous symptoms associated with it in males.

Early in the 1950s, Upjohn, now known as Pharmacia & Upjohn, introduced testosterone cypionate as Depo-Testosterone to the U.S. prescription medication market. Due to the testosterone cypionate and testosterone enanthate’s striking similarities, the former has gained only limited global distribution and is frequently mistaken for an American drug.

The main androgen in the body is testosterone. Species of cells in the testis, ovary, and adrenal cortex produce endogenous testosterone. In the treatment of either congenital or acquired hypogonadism, testosterone is employed. The best exogenous androgen for the palliative therapy of breast cancer in postmenopausal women is testosterone. In 1938, testosterone was in use, and the FDA gave its approval in 1939. Since they have been used illegally, anabolic steroids, which are testosterone derivatives, are now considered controlled substances. In 1991, testosterone, along with a number of anabolic steroids, was designated as a restricted substance. Parenterally given dosages of both standard and delayed-release (depot) testosterone are available. The FDA initially approved testosterone transdermal patches (Androderm) in September 1995; today, there are numerous transdermal brands, forms, and products available, including implants, gels, and topical treatments. In July 2003, the FDA authorized the Striant testosterone buccal system. This mucoadhesive device clings to the buccal mucosa and offers a controlled and sustained release of testosterone. The FDA authorized an intranasal gel formulation in May 2014. (Natesto). The use of a transdermal patch (Intrinsa) for female hormone replacement is being studied; daily dosages are substantially lower for female users than for male users. The FDA decided to postpone the approval of the Intrinsa women’s testosterone patch in late 2004 and has since demanded more safety information, particularly in regards to cardiovascular and breast health.

The cypionate ester is a type of chemical molecule that reacts with water to form alcohols and organic or inorganic acids. The majority of esters are made from carboxylic acids, and one or more esters are frequently supplied along with injectable testosterone. The testosterone molecule has an ester added to it, which affects how soluble it is after it enters the bloodstream. The ester is shorter and the drug is more soluble with a shorter carbon chain. A smaller or shorter object will have a shorter half life, which is the amount of time a medicine spends in the body twice. Long carbon chains, such as cypionate, work slowly on the body and expel the body at a similar rate, which is true in reverse.